Cipla Australia

Cipla: Founded in 1935, Cipla focuses on flexible, sustainable growth and the development of generic drugs, continuously optimizing its portfolio in India, South Africa, North America, and other key regulated and emerging markets. Cipla is widely recognized for its strengths in respiratory medicine, antiretrovirals, urology, cardiology, and central nervous system treatments. With 47 manufacturing sites worldwide, Cipla leverages its world-class technology platforms to produce over 1,500 products in more than 50 dosage forms, meeting the needs of over 80 markets globally. Its sales rank third in India’s pharmaceutical industry (IQVIA MAT, May 2022), third in South Africa’s private pharmaceutical market (IQVIA YTD, May 2022), and it is also one of the most well-known generic drug companies in the U.S. market. Over the past 80 years, Cipla has been committed to transforming patient access to medicines. In 2001, Cipla introduced a triple antiretroviral therapy for HIV/AIDS in Africa at less than $1 per day, a move that set an industry benchmark and was widely acknowledged for enhancing inclusivity, accessibility, and affordability in the fight against AIDS. As a highly responsible company, Cipla’s humanitarian strategies centered around the goal of "caring for life," along with its strong network of relationships established wherever it operates, have made it a trusted partner for global healthcare institutions, peers, and all stakeholders.